Clinical Trials on Prostatic Hyperplasia in New Zealand

Total 1400 results

ProstaCare Singapore Pte. Ltd.

Terminated

To Evaluate the Safety and Performance of the ProstaCare Water Electrolysis System in Relieving Symptoms of BPH.

Benign Prostatic Hyperplasia

Singapore, New Zealand
Zenflow, Inc.

Recruiting

The Zenflow Spring System EU Safety and Performance Study (ZEST EU)

Benign Prostatic Hyperplasia

Australia, New Zealand
Zenflow, Inc.

Unknown

The Zenflow Spring System Feasibility and Safety Study (ZEST)

Benign Prostatic Hyperplasia

Bulgaria, New Zealand
Light Sciences Oncology

Completed

Study of Light-Activated Talaporfin Sodium in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)

Lower Urinary Tract Symptoms | Benign Prostatic Hyperplasia

New Zealand, Australia
Resurge Therapeutics Inc.

Recruiting

RT-310 Dose Escalation BPH Study

Lower Urinary Tract Symptoms | BPH (Benign Prostatic Hyperplasia)

New Zealand, Australia
Nymox Corporation

Completed

Phase 2 Study of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) (Enlarged Prostate)

Benign Prostatic Hyperplasia (BPH) | Enlarged Prostate

United States
Medifocus, Inc.

Unknown

Post-Marketing Study Using PROLIEVE® for the Treatment of Benign Prostatic Hyperplasia (BPH)

Benign Prostate Hyperplasia

United States
Medi-Tate Ltd.

Completed

Pivotal Study to Assess the Safety and Effectiveness of the iTind Device

Benign Prostate Hyperplasia

United States, Canada
PROCEPT BioRobotics

Completed

Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue (WATER) (WATER)

Benign Prostatic Hyperplasia (BPH)

United States, Australia, United Kingdom, New Zealand
Weill Medical College of Cornell University

Completed

A Prospective Evaluation of the GreenLight Model 120 Laser

Benign Prostatic Hyperplasia

United States
Brooklyn Urology Research Group
American Medical Systems; Richard Wolf Medical Instruments Corporation (RWMIC)

Completed

Phase 4 Study of Greenlight XPS Laser Versus BiVAP Saline Vaporization of the Prostate in Men With Symptomatic Benign Prostatic Hyperplasia

Benign Prostatic Hyperplasia (BPH)

United States
Lumenis Be Ltd.

Unknown

Ablation Efficacy of Contact Side Firing Fiber in Predefined Settings for Treating BPH

Treatment of Benign Prostatic Hyperplasia

United States
Eli Lilly and Company

Completed

A Study in Benign Prostatic Hyperplasia

Benign Prostatic Hyperplasia

United States, Italy, Austria
National Institute of Diabetes and Digestive and...
George Washington University

Completed

Botulinum Toxin Injection for the Management of BPH (MIST2)

Benign Prostatic Hyperplasia

United States
Nymox Corporation

Completed

Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)

Benign Prostatic Hyperplasia

United States
Medi-Tate Ltd.

Terminated

A Multi-center, International Prospective Follow up Study

Benign Prostatic Hyperplasia (BPH)

Canada, United States
MedeonBio, Inc.

Active, not recruiting

Safety and Feasibility of the XFLO Expander System (Mercury) (EXPANDER-1)

Benign Prostatic Hyperplasia

Taiwan, Canada, Australia, Georgia
Watson Pharmaceuticals

Completed

A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo

Benign Prostatic Hyperplasia

United States
National Institute of Diabetes and Digestive and...
Merck Sharp & Dohme LLC; Medtronic; Sanofi-Synthelabo; Diagnostic Ultrasound; Uro...

Terminated

Minimally Invasive Surgical Therapy for BPH (MIST)

Benign Prostatic Hyperplasia

United States
Sanofi

Completed

The Efficacy, Onset of Effect, and Safety of Alfuzosin Once Daily in the Treatment of Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A Randomized, Placebo-Controlled Trial Using an Acute International Prostate Score (ALF-ACUTE)

Benign Prostatic Hyperplasia

United States
Merit Medical Systems, Inc.

Terminated

Prostate Artery Embolization With Embosphere Microspheres Compared to TURP for Benign Prostatic Hyperplasia

Benign Prostatic Hyperplasia

United States
Weill Medical College of Cornell University
Boston Scientific Corporation

Suspended

Catheterless Water Vapor Therapy for the Treatment of BPH

Benign Prostatic Hyperplasia

United States
Urotronic Inc.
ClinLogix. LLC

Active, not recruiting

A Clinical Study to Evaluate the Safety and Efficacy of the Optilume™ BPH Catheter System in Men With Symptomatic BPH (PINNACLE)

Benign Prostatic Hyperplasia

United States, Canada
En Chu Kong Hospital

Completed

The Changes of Urine Growth Factors Level

Benign Prostatic Hyperplasia

Taiwan
Nymox Corporation

Completed

Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018

Benign Prostatic Hyperplasia (BPH)

United States
NeoTract, Inc.

Completed

The Safety and Effectiveness of UroLift: LIFT Pivotal Study (LIFT)

Benign Prostatic Hyperplasia

United States, Australia, Canada
Sophiris Bio Corp

Completed

Randomized, Double-Blind, Vehicle-Controlled, Multicenter Safety and Efficacy Study of Intraprostatic PRX302 for LUTS BPH (PLUS-1)

Benign Prostatic Hyperplasia

United States, Australia, Canada, Russian Federation, Ukraine, New Zealand
American Medical Systems

Completed

A Long-Term Study Examining the Treatment of Benign Prostatic Hyperplasia With Photoselective Vaporization (PVP)

Benign Prostatic Hyperplasia

United States
Nymox Corporation

Completed

Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)

Benign Prostatic Hyperplasia

United States
Weill Medical College of Cornell University
Teleflex; NeoTract, Inc.

Suspended

Urolift Pre-SBRT for Reduced Urinary Toxicity in Patients With BPH and Prostate Cancer.

Benign Prostatic Hyperplasia

United States
Eli Lilly and Company

Completed

A Study of Tadalafil in Men With Benign Prostatic Hyperplasia Symptoms Who Are Being Treated With Alpha Blockers

Benign Prostatic Hyperplasia

United States, Puerto Rico
Antonios Likourezos

Withdrawn

Analysis of Prostatic Arterial Embolization for Benign Prostatic Hyperplasia Using Embosphere Microspheres

Benign Prostatic Hyperplasia

United States
QLT Inc.

Completed

Dose Escalation Study With QLT0074 for Benign Prostatic Hyperplasia

Benign Prostatic Hyperplasia

United States, Canada
Watson Pharmaceuticals

Completed

The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months

Benign Prostatic Hyperplasia

United States
Eli Lilly and Company
ICOS Corporation

Completed

Effects of Tadalafil Once a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia

Benign Prostatic Hyperplasia

United States, Greece, Portugal
OPKO Health, Inc.

Terminated

Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH)

Benign Prostatic Hyperplasia

United States
Threshold Pharmaceuticals

Terminated

Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia

Benign Prostatic Hyperplasia

United States
GlaxoSmithKline

Completed

A Study To Compare 3 Different Formulations Of Tamsulosin At Steady State.

Prostatic Hyperplasia

United States
Light Sciences Oncology
Mundipharma Research Limited

Completed

A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia

Benign Prostatic Hyperplasia

United States
GlaxoSmithKline

Completed

A Study Assessing a Range of Formulations of the Fixed Dose Combination Product Containing Dutasteride (0.5mg) and Tamsulosin Hydrochloride (0.2mg) to Find a Formulation Which is Bioequivalent to Harnal-D Tablets (Tamsulosin Hydrochloride, 0.2mg) in Healthy Male Subjects From North East Asia

Prostatic Hyperplasia

Australia
GlaxoSmithKline

Completed

A Study to Determine the Bioavailability of a Fixed Dose Combination Product of Dutasteride (0.5mg) and Tamsulosin Hydrochloride (0.2mg) Relative to Co-administration of the Individual Components in Healthy Male Subjects of North East Asian and Non-Asian Ancestry. (ARI114694)

Prostatic Hyperplasia

Australia
Artann Laboratories
National Cancer Institute (NCI); Mayo Clinic; University of Minnesota; Rutgers,...

Completed

Prostate Mechanical Imager (PMI) Clinical Bridging Study (PMI)

Prostatic Neoplasms | Prostatic Hyperplasia

United States
GlaxoSmithKline

Completed

Bioavailability of Two Combination Products of Dutasteride (0.5mg) and Tamsulosin Hydrochloride (0.2mg) in Asian Males. (ARI115707)

Prostatic Hyperplasia

Australia
Eli Lilly and Company

Completed

Study to Treat Patients Who Have Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) With Tadalafil Daily

Benign Prostatic Hyperplasia

Italy, United States, Germany, Mexico, Argentina
Eli Lilly and Company

Terminated

A Study in Men With Benign Prostatic Hyperplasia

Benign Prostatic Hyperplasia

United States, Germany, France, Australia, Greece, Canada, Russian Federation, Italy
GlaxoSmithKline

Completed

Effect Of Dutasteride On Intraprostatic Dihydrotestosterone (DHT) Levels

Prostatic Hyperplasia

United States
Watson Pharmaceuticals

Completed

A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo

Benign Prostatic Hyperplasia (BPH)

United States
Warner Chilcott

Completed

Assess Safety & Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

Benign Prostatic Hyperplasia

United States
Nymox Corporation

Completed

Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)

Benign Prostatic Hyperplasia | BPH | LUTS | Lower Urinary Tract Symptoms (LUTS)

United States
NeoTract, Inc.

Recruiting

Comparing UroLift Experience Against Rezūm (CLEAR)

Benign Prostatic Hyperplasia

United States, United Kingdom

Clinical Trials on Prostatic Hyperplasia in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Moldova

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations